Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing · Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. The information set forth in Item 5.02 of this Current Report on Form 8-K (this “Report”) regarding the resignation of Dr. Rodney A. Ferguson from the board of directors (the “Board”) of Launch One Acquisition Corp. (the “Company”) is incorporated by reference into this Item 3.01. As a result of Dr.…
Filed Nov 9, 2026Accepted Nov 9, 2026, 4:15 PM ESTCIK 2015502Accession 0001213900-26-117530
Launch One Acquisition Corp. is a company set up to merge with and take public an exciting business in healthcare or technology. Listed on Nasdaq under the ticker LPAA, Launch One is led by experienced leaders who want to support game-changing solutions. For more information, contact Jurgen van de Vyver at jurgen@launchpad.vc.
Select an item to read the extracted section. The as-filed document remains the primary evidence.
Item 3.01Item 3.01 - Notice of Delisting
Item 3.01. Notice of Delisting or Failure to Satisfy a Continued
Listing Rule or Standard; Transfer of Listing.
The information set forth in Item 5.02 of this
Current Report on Form 8-K (this “Report”) regarding the resignation of Dr. Rodney A. Ferguson from the board of directors
(the “Board”) of Launch One Acquisition Corp. (the “Company”) is incorporated by reference into
this Item 3.01.
As a result of Dr. Ferguson’s resignation,
the audit committee of the Board (the “Audit Committee”) is comprised of two members, Mr. Atwood and Mr. Rogers, and
the Company no longer complies with Nasdaq Listing Rule 5605(c)(2)(A), which requires that the audit committee of a listed company be
comprised of at least three members, each of whom must, among other things, be an independent director as defined under the Nasdaq listing
rules and meet the criteria for independence set forth in Rule 10A-3(b)(1) under the Securities Exchange Act of 1934, as amended (the
“Exchange Act”). On December 6, 2026, The Nasdaq Stock Market LLC (“Nasdaq”) notified the Company
of such noncompliance.
Nasdaq Listing Rule 5605(c)(4)(B) provides that,
where a listed company fails to comply with the audit committee composition requirements of Nasdaq Listing Rule 5605(c)(2)(A) due to a
single vacancy on the audit committee, the company will have a cure period to regain compliance until the earlier of (i) its next annual
meeting of shareholders and (ii) one year from the occurrence of the event that caused the noncompliance; provided, however, that if the
next annual meeting of shareholders is held no later than 180 days following the event that caused the vacancy, the company will instead
have 180 days from such event to regain compliance. The Company intends to rely on this cure period.
The Board intends to appoint a new independent
director who satisfies the applicable requirements of the Nasdaq listing rules and Rule 10A-3 under the Exchange Act to serve on the Board
and the Audit Committee prior to the expiration of the cure period. As of the date of this Report, no replacement director has been appointed,
and there can be no assurance as to the timing of any such appointment.
In addition, as a result of Dr. Ferguson’s
resignation, the Board is no longer comprised of a majority of independent directors, as required by Nasdaq Listing Rule 5605(b)(1). Nasdaq
Listing Rule 5605(b)(1)(A) provides a cure period on substantially the same terms as described above with respect to the Audit Committee.
On November 6, 2026, Nasdaq notified the Company of such noncompliance. The Company intends to rely on such cure period and expects to
regain compliance with Nasdaq Listing Rule 5605(b)(1) upon the appointment of a new independent director as described above.
The compensation committee of the Board is comprised
of two members, Mr. Atwood and Mr. Rogers.
Item 5.02Item 5.02 - Departure/Election of Directors
Item 5.02. Departure of Directors or Certain Officers; Election
of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On November 4, 2026, Dr. Rodney A. Ferguson notified
the Company of his decision to resign from the Board and as a member of the Audit Committee and the compensation committee of the Board,
effective immediately. Dr. Ferguson’s decision to resign was not the result of any disagreement with the Company on any matter relating
to the Company’s operations, policies or practices.
The information set forth in Item 3.01 of this
Report is incorporated by reference into this Item 5.02.